Altimmune Inc (ALT) Stock Price, Quote & News

Company Profile

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Industry: Biotechnology

Sector: Healthcare

Phone: 240 654 1450

Website: altimmune.com

Address:

910 Clopper Road, Suite 201S, Gaithersburg, United States

Turribull Jul. 4 at 7:01 PM

$ALT The irony here is thick. Most people try to hide their ignorance. Not you. You’re out here wearing it like a merit badge.

0 · Reply

CrappieDude Jul. 4 at 6:46 PM

$ALT so this is your ideal board? No thanks- many of the negative posts on ALT mgmt are well deserved. The science is super impressive and perhaps only rivaled by Durso/Garg missteps. The proof of this is now I see bullish posts here hoping stock price hits $10 before we get bought out with a 100% premium. Whoop-de-doo — this is not what longer term holders envisioned.

2 · Reply

BigCheeze2014 Jul. 4 at 6:44 PM

$ALT Goldmannnn Suchs is protecting its vast holdings:

0 · Reply

BuddyBoy6975 Jul. 4 at 6:34 PM

$ALT Another clown off to nowhere. Bub. Bye

0 · Reply

2ndComing Jul. 4 at 5:54 PM

$ALT Typical bag holder moans

1 · Reply

Addairbob Jul. 4 at 4:38 PM

$ALT Have a great weekend and be safe bulls ! 🥳 Find someone to drive if you drink. I lost a really good friend several years ago to a drunk driver on the 4th. 😎 🙌🏼🇺🇸🙌🏼🇺🇸🙌🏼

1 · Reply

Chucho64 Jul. 4 at 4:31 PM

$ALT Here's what I researched and what AI tells me: in small biotech or pharmaceutical companies (known as penny stocks or microcaps), positive news can send the stock price soaring 1,000%, 3,000%, or even more in a single day. These extreme spikes occur almost exclusively in companies with one or two drugs in development. How many drugs does ALT have?🤔🤔💯💥💎💰💯

1 · Reply

tmod300 Jul. 4 at 3:26 PM

$ALT I am very

0 · Reply

JuggernautRaider Jul. 4 at 3:25 PM

I agree wholeheartedly @DeepBlueCyan I met a fibromyalgia patient last night who I told how to get free Tonmya. She is a doctor of some sort here in New Jersey. 🇺🇸 She is also a cancer survivor and a tough cookie. 🍪 ask @PeteyUSA or @Proposition_Joe newbie 😋 So I say buy $TNXP . Fibromyalgia patients are waiting all over Hold $SLS - somebody may buy it or it may crash 🤷‍♂️ Buy $ALT - AUD data will be great And buy $IMRX to fight pancreatic cancer - perhaps the deadliest aside from metastatic small cell lung cancer. But Amgen and other companies are already crushing that space with a little DLL3 bispecific called Imdelltra. Google it if you want What business are you in DBC? I am in the Education business. And your price just went up to $84.99 my friend 😜

0 · Reply

Babybock Jul. 4 at 2:39 PM

$ALT I honestly can't understand people that are negative about this or any stock. First if you are invested in the stock and that negative you're an idiot to continue to hold sell and get the hell out. If you don't own the stock, don't waste your time being negative because I do not think you are that altruistic and trying to help. So you must have an alterior motive and NEED the stock to drop. That is why every person that wants this stock to succeed, just need to mute all the negative. They are not your friends. Holding long and very

6 · Reply

Altimmune initiated with an Outperform at Leerink

2026-06-22T10:31:03.000Z - 12 days ago

Altimmune initiated with an Outperform at Leerink

Jun 10, 2026, 8:00 AM EDT - 24 days ago

Altimmune Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 4, 2026, 12:50 PM EDT - 4 weeks ago

Altimmune Transcript: Jefferies Global Healthcare Conference 2026

2026-05-28T16:27:37.000Z - 5 weeks ago

Altimmune reports 48-week data from IMPACT Phase 2b trial of pemvidutide

May 28, 2026, 11:00 AM EDT - 5 weeks ago

Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026

May 27, 2026, 8:30 AM EDT - 5 weeks ago

Altimmune to Participate in Upcoming Investor Conferences

May 27, 2026, 8:00 AM EDT - 5 weeks ago

New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026

2026-05-18T15:36:37.000Z - 6 weeks ago

Altimmune price target lowered to $20 from $25 at H.C. Wainwright

May 14, 2026, 7:00 AM EDT - 7 weeks ago

Altimmune Slides: Corporate presentation

2026-05-14T09:47:49.000Z - 7 weeks ago

Altimmune price target lowered to $11 from $14 at Citizens

May 13, 2026, 8:30 AM EDT - 7 weeks ago

Altimmune Earnings Call Transcript: Q1 2026

May 13, 2026, 8:30 AM EDT - 7 weeks ago

Altimmune Earnings release: Q1 2026

May 13, 2026, 8:30 AM EDT - 7 weeks ago

Altimmune Quarterly report: Q1 2026

2026-05-13T11:59:47.000Z - 7 weeks ago

Altimmune reports Q1 EPS (18c), consensus (25c)

May 13, 2026, 7:30 AM EDT - 7 weeks ago

Altimmune Announces First Quarter 2026 Financial Results and Business Update

May 13, 2026, 7:15 AM EDT - 7 weeks ago

Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026

May 6, 2026, 7:30 AM EDT - 2 months ago

Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

2026-04-27T19:56:05.000Z - 2 months ago

Altimmune management to meet with Piper Sandler

Apr 27, 2026, 7:00 AM EDT - 2 months ago

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities

2026-04-24T09:16:13.000Z - 2 months ago

Altimmune upgraded to Neutral from Sell at Goldman Sachs

2026-04-23T11:06:36.000Z - 2 months ago

Altimmune 64.25M share Spot Secondary priced at $3.00

Apr 22, 2026, 11:25 PM EDT - 2 months ago

Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities

2026-04-22T20:28:30.000Z - 2 months ago

Altimmune announces common stock offering, no amount given

Apr 22, 2026, 4:19 PM EDT - 2 months ago

Altimmune Announces Proposed Underwritten Public Offering of Securities

Apr 16, 2026, 8:30 AM EDT - 2 months ago

Altimmune Transcript: AGM 2026

2026-03-18T20:00:19.000Z - 3 months ago

Altimmune initiated with a Buy at Truist

Mar 17, 2026, 8:00 AM EDT - 3 months ago

Altimmune Proxy statement: Proxy Filing

2026-03-16T16:15:11.000Z - 3 months ago

Altimmune price target raised to $25 from $12 at H.C. Wainwright

Mar 12, 2026, 10:30 AM EDT - 4 months ago

Altimmune Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 11, 2026, 9:20 AM EDT - 4 months ago

Altimmune Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 2:15 PM EDT - 4 months ago

Altimmune Transcript: The Citizens Life Sciences Conference 2026

Mar 9, 2026, 7:00 AM EDT - 4 months ago

Altimmune Slides: Corporate presentation

2026-03-06T13:40:07.000Z - 4 months ago

Altimmune price target lowered to $13 from $18 at B. Riley

Mar 6, 2026, 7:00 AM EST - 4 months ago

Altimmune Proxy statement: Proxy Filing

Mar 5, 2026, 8:30 AM EST - 4 months ago

Altimmune Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:30 AM EST - 4 months ago

Altimmune Annual report: Q4 2025

Mar 5, 2026, 8:30 AM EST - 4 months ago

Altimmune Earnings release: Q4 2025

2026-03-05T12:14:56.000Z - 4 months ago

Altimmune reports Q4 EPS (27c), consensus (24c)

Mar 5, 2026, 7:00 AM EST - 4 months ago

Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates

Feb 26, 2026, 7:30 AM EST - 4 months ago

Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

2026-02-20T14:12:05.000Z - 4 months ago

Altimmune management to meet with Piper Sandler

2026-02-13T14:55:31.000Z - 5 months ago

Altimmune initiated with a Buy at Titan Partners

Feb 3, 2026, 1:27 PM EST - 5 months ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

AMGN GPCR LLY NVO PFE VKTX

Jan 29, 2026, 5:54 PM EST - 5 months ago

Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock

Jan 27, 2026, 9:25 PM EST - 5 months ago

Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock

Jan 5, 2026, 7:30 AM EST - 6 months ago

Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH

Dec 19, 2025, 8:00 AM EST - 7 months ago

Altimmune Transcript: Study Result

Dec 19, 2025, 8:00 AM EST - 7 months ago

Altimmune Press release: Study Result

Dec 19, 2025, 8:00 AM EST - 7 months ago

Altimmune Slides: Study Result

Dec 19, 2025, 6:42 AM EST - 7 months ago

Altimmune's drug for a type of liver disease shows benefits in mid-stage study

Dec 19, 2025, 6:30 AM EST - 7 months ago

Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

Dec 3, 2025, 2:30 PM EST - 7 months ago

Altimmune Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 1, 2025, 7:30 AM EST - 7 months ago

Altimmune Announces CEO Transition and Succession Plan

Nov 26, 2025, 7:30 AM EST - 7 months ago

Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 20, 2025, 3:00 AM EST - 8 months ago

Altimmune Transcript: Jefferies London Healthcare Conference 2025

Nov 13, 2025, 7:00 AM EST - 8 months ago

Altimmune Registration statement: Registration Filing

Nov 12, 2025, 10:00 AM EST - 8 months ago

Altimmune Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 8:51 AM EST - 8 months ago

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025

Nov 7, 2025, 8:05 AM EST - 8 months ago

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025

Nov 6, 2025, 4:00 PM EST - 8 months ago

Altimmune Slides: Corporate Presentation

Nov 6, 2025, 8:30 AM EST - 8 months ago

Altimmune Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 8 months ago

Altimmune Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 8 months ago

Altimmune Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 8 months ago

Altimmune Announces Third Quarter 2025 Financial Results and Business Updates

Nov 6, 2025, 7:00 AM EST - 8 months ago

Altimmune Registration statement: Registration Filing

Nov 5, 2025, 7:30 AM EST - 8 months ago

Altimmune to Participate in Two Upcoming Investor Conferences

Nov 3, 2025, 7:30 AM EST - 8 months ago

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

Oct 30, 2025, 7:30 AM EDT - 8 months ago

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Oct 21, 2025, 7:00 AM EDT - 9 months ago

Altimmune Transcript: H.C. Wainwright Liver Disease Virtual Conference

Oct 20, 2025, 7:30 AM EDT - 9 months ago

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025

Sep 30, 2025, 10:30 AM EDT - 9 months ago

Altimmune Transcript: Stifel Virtual Cardiometabolic Forum

Sep 29, 2025, 7:30 AM EDT - 9 months ago

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

Sep 25, 2025, 8:30 AM EDT - 10 months ago

Altimmune Transcript: AGM 2025

Sep 15, 2025, 7:30 AM EDT - 10 months ago

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

Sep 10, 2025, 7:45 AM EDT - 10 months ago

Altimmune Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 8:30 AM EDT - 10 months ago

Altimmune Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 19, 2025, 7:30 AM EDT - 11 months ago

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Turribull Jul. 4 at 7:01 PM

$ALT The irony here is thick. Most people try to hide their ignorance. Not you. You’re out here wearing it like a merit badge.

0 · Reply

CrappieDude Jul. 4 at 6:46 PM

2 · Reply

BigCheeze2014 Jul. 4 at 6:44 PM

$ALT Goldmannnn Suchs is protecting its vast holdings:

0 · Reply

BuddyBoy6975 Jul. 4 at 6:34 PM

$ALT Another clown off to nowhere. Bub. Bye

0 · Reply

2ndComing Jul. 4 at 5:54 PM

$ALT Typical bag holder moans

1 · Reply

Addairbob Jul. 4 at 4:38 PM

1 · Reply

Chucho64 Jul. 4 at 4:31 PM

1 · Reply

tmod300 Jul. 4 at 3:26 PM

$ALT I am very

0 · Reply

JuggernautRaider Jul. 4 at 3:25 PM

0 · Reply

Babybock Jul. 4 at 2:39 PM

6 · Reply

stockro1 Jul. 4 at 2:28 PM

$IXHL The market has a habit of mispricing companies when the story changes faster than the valuation. I think that’s happening here. • Targeting one of the world’s largest unmet medical markets (Obstructive Sleep Apnoea) • Positive Phase 2 efficacy • Strong balance sheet, minimal debt • Multiple catalysts ahead • Small share count • Valuation that still looks modest if development succeeds This is now an execution story. Today’s valuation appears to price in far more failure than success. Watching for: ✔️ First patient dosed ✔️ Clinical progress ✔️ Institutional buying ✔️ Strategic partnerships The biggest gains often come before consensus catches up. Do your own research. $IXHL $VKTX $ALT $HIMS $LLY

3 · Reply

mark420420 Jul. 4 at 2:18 PM

$ALT after the price action last week, I think we're in for a big week coming. 🤞🤞

0 · Reply

Designed2Gain Jul. 4 at 1:46 PM

$ALT

1 · Reply

GreenEnergy7B Jul. 4 at 1:15 PM

$ALT We back in New York for the match against Brazil tomorrow https://www.youtube.com/shorts/S_zE5szUgGE $SLS $MU $IQMX $NBIS

0 · Reply

JuggernautRaider Jul. 4 at 1:12 PM

$SLS @FUD_Slayer i love fighting acute myeloid leukemia as much as the next guy but, one of my Golden Rules of Thumb that my Irish friend @AkBearHunter knows: if you have made a 900% return (10 X), why are you still holding? Go for 1000% (11x) or 1900% (19x) ? Love the spunk but $ALT $IXHL and $TNXP could all 5x, 10x, or 20x the next year (boom! 💥) Or, they could go bust faster than the Titantic 🛳️ Welcome to biopharma. Ask my guy @Night_Owl_Biotech . He is wicked smart too 😉 @alphaonetrading has been quiet lately 🤫 I should be too.

3 · Reply

Diapers_Tequila Jul. 4 at 11:29 AM

$ALT

1 · Reply

golfeveryday Jul. 4 at 11:02 AM

$ALT AUD estimated primary completion May 2026 and study completion June 2026. So, during planning, I assume this means they expected 4 weeks to lock, clean and evaluate the data? Any day I guess.

1 · Reply

2ndComing Jul. 4 at 10:12 AM

$ALT ya ya.. go watch your never ending story fantasy again...

0 · Reply

Paul4321 Jul. 4 at 9:47 AM

$ALT Late July to mid August IMO MASH/AUD news. I dont try to guess on SP since the powers that be have eyes on the boards (and rats), and will manipulate you the more ammunition you give them to work with.

0 · Reply

BuddyBoy6975 Jul. 4 at 4:39 AM

$ALT We’ve checked ALL these boxes.

0 · Reply

BuddyBoy6975 Jul. 4 at 4:37 AM

$ALT Hey. U R Here

0 · Reply

Bwill15 Jul. 4 at 1:27 AM

$ALT Computer knows all!: “Pemvidutide's chances for success in AUD are strongly supported by its highly successful Phase 2b clinical data in MASH (Metabolic Dysfunction-Associated Steatohepatitis). In those trials, pemvidutide achieved statistically significant reductions in liver fat content, inflammation, and fibrosis, along with profound weight loss. Because the neurological pathways that drive food and alcohol cravings overlap, its proven track record in metabolic diseases translates to a strong likelihood of efficacy in addiction and substance use.”

0 · Reply

Market Cap	614.54M
Revenue (ttm)	40,000.00
Net Income (ttm)	-88.09M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-220,225.00%
Debt to Equity Ratio	0.15

Volume	4,077,500
Avg Vol	4,711,962
Day's Range	N/A - N/A
Shares Out	194.47M
Stochastic %K	64%
Beta	0.25
Analysts	Strong Sell
Price Target	$12.95